Remove 2030 Remove Biopharma Remove Strategic partnership
article thumbnail

The Future of Proteomics: Innovations, Challenges, and Industry Growth (2024-2030)

Frost & Sullivan

The global proteomics industry is poised for significant expansion between 2024 and 2030, driven by advances in research and pharmaceutical applications. Strategic partnerships with bioinformatics firms and academic institutions will drive next-gen proteomics innovations. of Competitors 80, with revenue greater than $1.0

article thumbnail

DCAT Week 2025: Key Takeaways & Industry Advancements

Frost & Sullivan

With 87% of biopharma manufacturers targeting renewable electricity by 2030, CDMOs must align with evolving sustainability regulations and partner expectations. trillion in 2024, is expected to grow at a 7% CAGR through 2030. Want to Learn More?